NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.90 USD | +1.75% |
|
+0.90% | +13.19% |
| 09-03 | NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor | MT |
| 09-03 | Novocure Announces CEO Changes, Effective January 1, 2025 | CI |
Company Valuation: NovoCure Limited
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,340 | 17,615 | 7,795 | 7,698 | 1,595 | 1,829 | - | - |
| Change | - | 111.21% | -55.75% | -1.24% | -79.27% | 14.63% | - | - |
| Enterprise Value (EV) 1 | 8,312 | 17,810 | 8,148 | 8,148 | 1,923 | 1,895 | 2,152 | 2,025 |
| Change | - | 114.27% | -54.25% | 0% | -76.39% | -1.5% | 13.61% | -5.91% |
| P/E ratio | -1,204x | 865x | -134x | -83.4x | -7.66x | -12.6x | -12x | -12.6x |
| PBR | 38.5x | 37.2x | 19x | - | - | - | - | - |
| PEG | - | -2x | 0x | -1.5x | -0x | 0.4x | -2.36x | 2.53x |
| Capitalization / Revenue | 23.7x | 35.6x | 14.6x | 14.3x | 3.13x | 3.15x | 2.97x | 2.68x |
| EV / Revenue | 23.7x | 36x | 15.2x | 15.1x | 3.78x | 3.26x | 3.5x | 2.96x |
| EV / EBITDA | 1,102x | 450x | -239x | -103x | -8.67x | -11.6x | -12.6x | -13.2x |
| EV / EBIT | -9,094x | 586x | -184x | -91x | -8.26x | -11.6x | -12.4x | -12.6x |
| EV / FCF | 515x | 212x | 139x | 864x | -19.2x | -25.1x | -33.8x | -19.1x |
| FCF Yield | 0.19% | 0.47% | 0.72% | 0.12% | -5.22% | -3.98% | -2.95% | -5.23% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.07 | 0.2 | -0.56 | -0.88 | -1.95 | -1.345 | -1.414 | -1.343 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 351.3 | 494.4 | 535 | 537.8 | 509.3 | 580.4 | 615.8 | 683.5 |
| EBITDA 1 | 7.546 | 39.55 | -34.08 | -78.9 | -221.9 | -162.8 | -171.2 | -153.5 |
| EBIT 1 | -0.914 | 30.4 | -44.33 | -89.52 | -232.9 | -163.5 | -174.2 | -161 |
| Net income 1 | -7.23 | 19.81 | -58.35 | -92.53 | -207 | -145.9 | -154 | -146.5 |
| Net Debt 1 | -27.9 | 195.2 | 353.4 | 450.2 | 328 | 65.66 | 323.6 | 196.5 |
| Reference price 2 | 84.27 | 173.04 | 75.08 | 73.35 | 14.93 | 16.90 | 16.90 | 16.90 |
| Nbr of stocks (in thousands) | 98,969 | 101,797 | 103,819 | 104,950 | 106,861 | 108,217 | - | - |
| Announcement Date | 27/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E ratio | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -12.56x | 3.26x | -11.64x | - | 1.83B | ||
| 280.48x | 6.4x | 51.41x | -.--% | 7.93B | ||
| 62.75x | 1.98x | 10.44x | - | 6.15B | ||
| 22.75x | 1.94x | 10.6x | +2.13% | 5.75B | ||
| 45.86x | 6.9x | 23.11x | +0.65% | 5.22B | ||
| 52.25x | - | - | +0.53% | 4.76B | ||
| 14.44x | - | - | +1.97% | 4.43B | ||
| -41.24x | 4.18x | -75.23x | -.--% | 2.61B | ||
| 50.25x | 4.64x | 30.02x | +0.55% | 2.13B | ||
| Average | 52.78x | 4.19x | 5.53x | +0.83% | 4.53B | |
| Weighted average by Cap. | 80.12x | 4.33x | 15.81x | +0.86% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- NVCR Stock
- Valuation NovoCure Limited
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition